8-K: Prelude Therapeutics Announces Promising Clinical and Preclinical Data for SMARCA Degrader Portfolio

Prelude Therapeutics presented updated clinical data from its PRT3789 trial and preclinical data on its novel SMARCA2/4 dual degrader antibody conjugate program at the 36th EORTC-NCI-AACR Symposium.

Summary

• Prelude Therapeutics has released updated interim data from its Phase 1 trial of PRT3789, a SMARCA2 degrader, showing additional clinical activity at higher doses in non-small cell lung cancer (NSCLC) patients.
• The company also presented initial safety data from a combination study of PRT3789 and docetaxel, which demonstrated an acceptable safety profile.
• Preclinical proof-of-concept data was presented for a precision antibody drug conjugate program using a novel SMARCA2/4 dual degrader payload.
• The Phase 1 trial of PRT3789 included 65 patients with advanced solid tumors, with follow-up data reported up to September 23, 2024.
• Four patients with NSCLC or esophageal cancer experienced confirmed partial responses, including two NSCLC patients at doses of 283 mg or higher.
• Higher doses of PRT3789 resulted in deeper and more sustained SMARCA2 degradation in peripheral blood mononuclear cells (PBMCs).
• The company is also developing a precision antibody drug conjugate (ADC) using a SMARCA2/4 dual degrader payload, which has shown promising preclinical results.
• The company expects to conclude monotherapy dose escalation for PRT3789 by the end of 2024 and identify a biologically active dose for future trials.
• Enrollment is ongoing for back-fill cohorts enriched for NSCLC and SMARCA4 loss-of-function mutations at higher dose levels.

Sentiment

Score: 8

Explanation: The document presents positive clinical and preclinical data, indicating progress in the development of novel cancer therapies. The company is on track with its clinical trials and has a clear strategy for future development. The sentiment is positive, but with the understanding that the company is still in the early stages of clinical development.

Positives

• PRT3789 demonstrated promising clinical activity, with partial responses observed in NSCLC and esophageal cancer patients.
• The safety profile of PRT3789, both as a monotherapy and in combination with docetaxel, appears to be acceptable.
• The novel SMARCA2/4 dual degrader payload shows potential for expanding the reach of SMARCA degraders to cancers without SMARCA4 mutations.
• The company is progressing its pipeline with multiple clinical trials and preclinical programs.
• The company has a strategic collaboration with AbCellera to develop precision ADCs.
• The company has identified a biologically active dose for PRT3789.

Negatives

• The study is still in Phase 1, and further data is needed to confirm the efficacy of PRT3789.
• Some patients experienced treatment-emergent adverse events, such as nausea, fatigue, and anemia, although these were generally mild to moderate.
• A maximum tolerated dose for PRT3789 has not yet been identified.

Risks

• The clinical development of PRT3789 and other drug candidates is subject to risks and uncertainties, including the ability to enroll patients and achieve regulatory approvals.
• The company's ability to fund development activities and achieve development goals is subject to financial risks.
• The company faces competition from other companies developing cancer therapies.
• The success of the precision ADC program is dependent on the ability to identify and develop effective antibody-payload combinations.

Future Outlook

The company plans to continue dose escalation for PRT3789, initiate a Phase 2 trial in combination with pembrolizumab, and advance its precision ADC program. They expect to identify a biologically active dose for PRT3789 by the end of 2024 and share additional clinical activity data in 2025.

Management Comments

• Jane Huang, M.D., President and Chief Medical Officer, stated that they are encouraged by the promising activity shown to date by PRT3789.
• Peggy Scherle, Ph.D., Chief Scientific Officer, stated that the preclinical data offers first proof-of-concept of effectively and safely targeting an important mechanism to treat cancers beyond those with SMARCA4 mutations.

Industry Context

This announcement is significant as it highlights the progress in developing targeted therapies for cancers with SMARCA4 mutations, which are often difficult to treat with standard therapies. The development of SMARCA2 degraders and precision ADCs represents a novel approach in the field of precision oncology.

Comparison to Industry Standards

• The median progression-free survival for first-line SMARCA4-mutated NSCLC treated with chemoimmunotherapy is 2.7 months, and response rates are approximately 22%, as reported by Alessi et al. The interim objective response rate of 22.2% observed in NSCLC patients with Class I SMARCA4 mutations at doses of 283 mg or higher is comparable to these industry benchmarks.
• The company's approach of using a SMARCA2/4 dual degrader payload in ADCs is a novel strategy compared to traditional ADCs that use cytotoxic payloads.

Stakeholder Impact

• Shareholders: The positive clinical and preclinical data may positively impact the company's stock price.
• Patients: The development of new therapies may provide new treatment options for patients with SMARCA4-mutated cancers.
• Employees: The progress in clinical trials and preclinical programs may boost employee morale and job security.
• Partners: The collaboration with AbCellera may lead to new opportunities and revenue streams.

Next Steps

• Continue dose escalation for PRT3789 monotherapy.
• Enroll backfill cohorts enriched for NSCLC and esophageal cancer with Class I loss-of-function mutations.
• Initiate a Phase 2 trial of PRT3789 in combination with pembrolizumab.
• Further characterize the activity of PRT3789 in Class 1 vs Class 2 patients.
• Share initial clinical activity data on the combination of PRT3789 with docetaxel in 2025.
• Advance the precision ADC program with AbCellera.

Key Dates

Keywords

SMARCA2 degrader, PRT3789, SMARCA4 mutation, precision oncology, antibody drug conjugate, NSCLC, targeted protein degradation, cancer therapy, clinical trial, EORTC-NCI-AACR